Screener
Tyra Biosciences, Inc. TYRA MUC — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220645
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Dabogratinib LG-UTUC | $2,440 | — |
| Dabogratinib IR NMIBC | 5,248 | 1,290 |
| Dabogratinib ACH | 4,309 | 3,587 |
| Dabogratinib mUC | 1,614 | 3,255 |
| TYRA-430 HCC | 2,046 | 2,293 |
| TYRA-200 ICC | 1,010 | 1,465 |
| FGFR discovery | 2,532 | 3,132 |
| Other development programs | 849 | 514 |
Item 1. Condensed Financial Statements
FAQ
- What is Tyra Biosciences, Inc.'s MUC — research and development expense?
- Tyra Biosciences, Inc. (TYRA) reported MUC — research and development expense of $1.61M in Q1 2026.
- What does MUC — research and development expense mean?
- This metric represents the total operating costs directly attributable to research and development activities within the MUC business segment. It encompasses expenditures related to drug discovery, preclinical studies, and clinical trial execution for programs managed under this specific operational unit. Tracking these expenses provides insight into the company's investment intensity and progress toward commercializing its precision medicine pipeline.
Ask your AI about Tyra Biosciences, Inc.'s muc — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude